Neurocrine Biosciences CMO gets 8,314 stock options

The option award's first vesting date is December 4, 2026; RSU settlements are set for four dates from November 4, 2027, through November 4, 2030.

Available on EDGAR 11/05/2026 - 04:11 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Neurocrine Biosciences (NBIX) Chief Medical Officer Eiry Roberts received an award of 8,314 stock options and 1,506 restricted stock units on November 4, 2026. The options have an exercise price of $166.05 per share; 1/48 of the underlying shares becomes vested and exercisable on December 4, 2026, with an additional 1/48 each month thereafter. The options expire November 4, 2036. Each RSU represents a contingent right to one common share and settles in annual installments of 1/4 on November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.

Insider Trade Summary

Grant/Award: 9,820 shares

Grant/Award 2 txns

Insider ROBERTS EIRY

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F1	8,314	$0.00	$0.00
Grant/Award	Restricted Stock Unit F2, F3	1,506	$0.00	$0.00

Holdings After Transaction: Stock Option — 8,314 contracts (Direct); Restricted Stock Unit — 1,506 contracts (Direct)

Footnotes (3)

1. F1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 4, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
3. F3. The Restricted Stock Units will settle annually at 1/4 of the units settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.

Key Figures

Stock option award: 8,314 stock options Exercise price: $166.05 per share Option vesting: 1/48 of underlying shares initially; an additional 1/48 each month +3 more

6 metrics

Stock option award 8,314 stock options Granted November 4, 2026

Exercise price $166.05 per share Stock options granted November 4, 2026

Option vesting 1/48 of underlying shares initially; an additional 1/48 each month Initial vesting and exercisability date: December 4, 2026

Option expiration November 4, 2036 Stock options granted November 4, 2026

Restricted stock units 1,506 units Granted November 4, 2026

RSU settlement 1/4 of the units annually Settlement dates: November 4, 2027; November 4, 2028; November 4, 2029; November 4, 2030

Key Terms

Stock Option, Restricted Stock Unit, vested and exercisable, contingent right

4 terms

Stock Option financial

"Represents option of which 1/48th of the shares underlying the option becomes vested"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vested and exercisable financial

"becomes vested and exercisable on December 4, 2026"

contingent right financial

"represents a contingent right to receive one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When do Eiry Roberts' NBIX restricted stock units settle?

Each of the 1,506 restricted stock units represents a contingent right to one share of Neurocrine Biosciences common stock. They settle annually in four installments, with one-quarter settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROBERTS EIRY

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$166.05	11/04/2026		A		8,314		(1)	11/04/2036	Common Stock	8,314	$0	8,314	D
Restricted Stock Unit	(2)	11/04/2026		A		1,506		(3)	(3)	Common Stock	1,506	$0	1,506	D

Explanation of Responses:

1. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on December 4, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

3. The Restricted Stock Units will settle annually at 1/4 of the units settling on each of November 4, 2027, November 4, 2028, November 4, 2029, and November 4, 2030.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)